NattoPharma (OSL:NATTO) 10th of September 2008, Lysaker - NattoPharma and PL Thomas are pleased to announce that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans. Accepted by the journal Atherosclerosis, this study is now available online. http://www.atherosclerosis-journal.com/article/S0021-9150(08)00507-8/abstract
Researchers at University Medical Center Utrecht, Wageningen University and Erasmus Medical Center Rotterdam investigated whether daily consumption of natural phylloquinone (K1) and menaquinones (K2) might be related to the extent of calcification within the vasculature of 564 healthy post-menopausal women. This study was undertaken to examine the hypothesis that natural vitamin K plays a crucial role in the prevention of heart disease. The study discovered that high consumption of natural vitamin K2, about 45 mcg daily, was associated with 20% decreased coronary calcification as compared with low consumption of K2, of about 18mcg daily. Preventing arterial calcification is important for a healthy and flexible vasculature. Further, for Vitamin K1 no such correlation was found.
"This study confirms once again that natural Vitamin K2, also called the menaquinones, are clearly linked to the prevention of cardiovascular disease," said Vitamin K expert Leon J Schurgers, senior scientist from VitaK, at the Maastricht University in the Netherlands. "While all K vitamins are important, it seems that especially the natural vitamin K2 intake is essential to cardiovascular health."
LINK: http://hugin.info/137386/R/1250296/271580.pdf
NattoPharma
http://www.nattopharma.com
ISIN: NO0010289200
Stock Identifier: OSE.NATTO
Researchers at University Medical Center Utrecht, Wageningen University and Erasmus Medical Center Rotterdam investigated whether daily consumption of natural phylloquinone (K1) and menaquinones (K2) might be related to the extent of calcification within the vasculature of 564 healthy post-menopausal women. This study was undertaken to examine the hypothesis that natural vitamin K plays a crucial role in the prevention of heart disease. The study discovered that high consumption of natural vitamin K2, about 45 mcg daily, was associated with 20% decreased coronary calcification as compared with low consumption of K2, of about 18mcg daily. Preventing arterial calcification is important for a healthy and flexible vasculature. Further, for Vitamin K1 no such correlation was found.
"This study confirms once again that natural Vitamin K2, also called the menaquinones, are clearly linked to the prevention of cardiovascular disease," said Vitamin K expert Leon J Schurgers, senior scientist from VitaK, at the Maastricht University in the Netherlands. "While all K vitamins are important, it seems that especially the natural vitamin K2 intake is essential to cardiovascular health."
LINK: http://hugin.info/137386/R/1250296/271580.pdf
NattoPharma
http://www.nattopharma.com
ISIN: NO0010289200
Stock Identifier: OSE.NATTO
| Tweet |
 |
Related Companies |
>>> NattoPharma |
| |
Related Industry Topics: |
European Finance News | |
| |
This Page Viewed: (Last 30 Days: 50) (Since Published: 3140) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
